[go: up one dir, main page]

EP0692491B1 - Virussicheres stabiles pharmazeutisches Präparat bestehend aus wenigstens 70%, bevorzugt 90% humanem monomerem Immunglobulin A und Verfahren zu seiner Herstellung - Google Patents

Virussicheres stabiles pharmazeutisches Präparat bestehend aus wenigstens 70%, bevorzugt 90% humanem monomerem Immunglobulin A und Verfahren zu seiner Herstellung Download PDF

Info

Publication number
EP0692491B1
EP0692491B1 EP95110512A EP95110512A EP0692491B1 EP 0692491 B1 EP0692491 B1 EP 0692491B1 EP 95110512 A EP95110512 A EP 95110512A EP 95110512 A EP95110512 A EP 95110512A EP 0692491 B1 EP0692491 B1 EP 0692491B1
Authority
EP
European Patent Office
Prior art keywords
iga
pharmaceutical preparation
stable pharmaceutical
immunoglobulin
igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP95110512A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0692491A1 (de
Inventor
Josef W. Prof. Dr. Mannhalter
Heinz Dr. Leibl
Martha Prof. Dr. Eibl
Regine Dipl.-Ing. Tomasits
Hermann Dr. Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter AG
Original Assignee
Baxter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter AG filed Critical Baxter AG
Publication of EP0692491A1 publication Critical patent/EP0692491A1/de
Application granted granted Critical
Publication of EP0692491B1 publication Critical patent/EP0692491B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation

Definitions

  • the invention relates to a virus-safe stable pharmaceutical preparation consisting of at least 70%, preferably 90% human monomeric Immunoglobulin A (IgA) and a process for its preparation.
  • a virus-safe stable pharmaceutical preparation consisting of at least 70%, preferably 90% human monomeric Immunoglobulin A (IgA) and a process for its preparation.
  • Immunoglobulins are specific defense proteins in the Blood plasma, the lymph and other body secretions of all Vertebrates.
  • the immunoglobulins are derived from B lymphocytes synthesized.
  • the monomeric immunoglobulins consist of each two L (light) and H (heavy) chains through disulfide bridges are interconnected.
  • the immunoglobulins are Glycoproteins that act as antibodies and their Education is induced by antigens. Make in bulk they make up about 20% of the total plasma protein.
  • IgA, IgD, IgE, IgG and IgM that are in their H chains, in their serum concentration, the molecular weight (approx.
  • the main classes IgA and IgG can still be divided into subclasses (e.g. IgA1, IgA2).
  • the variety of immunoglobulin classes and subclasses as well as their diverse, different specificity in the Binding of antigens comes through a combination of different existing genetic components. On the induced formation of immunoglobulins is based on active Immunization while passive immunization against various virus and bacterial infections pre-formed Immunoglobulins are supplied.
  • Immunoglobulin A (IgA) is the main antibody class in external secretions such as saliva, tear fluid and the Mucus of the bronchial and intestinal tract. Thus immunoglobulin A serves as one of the first lines of defense against bacterial and viral antigens.
  • compositions based on immunoglobulins e.g. of immunoglobulin A, proposed and used (see e.g. JP-A-57-59815).
  • IgA can be derived from a receptor, the secretory component, through the epithelial cells from the blood side to the extracellular side to be transported.
  • IgA In the pure monomeric form, IgA consists of two light ones (L) and two heavy (H) chains; in the dimeric secretory form are two such monomers through the so-called J chain (joining chain) coupled together.
  • J chain joining chain
  • IgA as an IgA monomer is in equilibrium with IgA dimer in front. In this equilibrium the proportion of dimeric IgA a maximum of about 25% of the total IgA.
  • IgA consists of two subclasses, IgA1 and IgA2, in one native ratio of about 80 wt .-% to 20 wt .-%.
  • the native ratio of kappa to lambda light chains in an immunoglobulin preparation is about 1: 1.
  • IgA represents only about 3-4% of the total protein from normal human serum. Since IgA has a pronounced tendency to Complex formation and aggregation during cleaning, is the isolation of the monomeric IgA from serum mostly with low yield associated. Among the numerous Only a few manufacturing processes are known to date are also suitable for large-scale production.
  • the main contaminants of the IgA preparations are different subclasses of immunoglobulin G, their Separation additional, the yield of IgA continues reducing, cleaning methods require.
  • the known and common methods for cleaning Immunoglobulins are mostly based on differences in the physical properties, e.g. Solubility in aqueous systems (cleaning by fractional precipitation), Share of loads (cleaning by Ion exchange chromatography), or differences in the Molecular size (cleaning by Molecular exclusion chromatography).
  • JP-A-57-59815 describes a purification of immunoglobulins described from human starting material. Thereby will prior to precipitation with ammonium sulfate, gel filtration to Sephacryl® S-200 and then to separate the IgG affinity chromatography performed by IgA. Because of the very similar molecular weights of monomeric IgA and IgG (IgA: 162 kD, IgG: 153 kD; see J.F. Heremans, Immunoglobulin A, in: The Antigens, Vol. 2 [1974], pages 365-522; Academic Press New York) is an isolation from monomeric IgA, however, difficult.
  • the purified IgA as an active ingredient in pharmaceutical compositions is used and for the purification of human starting material is used, no measures are taken according to JP-A-57-59815 described for inactivating viruses.
  • the IgA is also located in capsules or pellets, which do not have a method for Inactivation of viruses can be subjected and in special can not be heat treated.
  • viruses are depleted / inactivated by more than 10 15 units (see, for example, Wells et al., Transfusion 26 (1986) 210-213), in particular when using a new one Cleaning procedure, still the risk of inadequate virus inactivation, ie insufficient virus security.
  • heat treatment can be carried out, for example.
  • the heat treatment has the Advantage that non-lipid-enveloped viruses such as for example, hepatitis A viruses.
  • Heat treatment without stabilizers is e.g. in EP-B-0159311 described. After that, the blood products are in moist (between 5 and 70% water content) solid state heated for one second to 100 hours.
  • Water can also contain compounds containing hydroxyl groups, such as e.g. Methanol, ethanol or mannitol can be used.
  • U.S. Patent 5,528,177 describes a method of making an IgA-enriched preparation. In doing so but IgA antibodies generally purified and not especially monomeric IgA antibodies. Furthermore, all included Preparations described in this document at least 30 up to 40% IgG.
  • EP-A-0525502 describes a process for the production of virus inactivated immunoglobulin solutions. These solutions can be injected intravenously and are virus free.
  • the object of the present invention is to provide a pharmaceutical preparation containing human to provide virus-safe monomer immunoglobulin A (IgA), which is essentially free of immunoglobulin G (IgG), and that can be obtained in a simple and safe manner, and with which the above in connection with the state of the Have the technology identified problems avoided. This task is solved with the subject of the present invention.
  • IgA virus-safe monomer immunoglobulin A
  • IgG immunoglobulin G
  • the invention relates to a pharmaceutical preparation containing virus-safe monomeric IgA according to claim 1, which is essentially free of IgG and by purifying an immunoglobulin-containing fraction and Implementation of a procedure for inactivating viruses is available.
  • Essentially free of IgG means the percentage of IgG on the total immunoglobulin is less than 10% by weight, and preferably less than 5% by weight, and especially less than 3% by weight.
  • the monomeric IgA is also essentially free of IgG dimers.
  • Essentially free of IgG dimers means that the proportion of IgG dimers on Total immunoglobulin is less than 5% by weight, and preferably less than 3 wt .-%, and especially below that Detection limit of radial immunodiffusion (RID) is.
  • Virus-safe monomeric IgA is preferably also free of Fibrinogen and / or free of plasminogen. Free from fibrinogen and / or plasminogen means that these Contamination with conventional tests, e.g. by means of Radial immunodiffusion (RID), coagulation tests or Fibrinolysis tests, are undetectable. In this way it is ensured that in the inventive Preparations and pharmaceutical containing them Compositions does not contain any substance that is in the Administration of the immunoglobulin additionally the organism could burden.
  • RID Radial immunodiffusion
  • Preferred embodiments thereof are the subject of Claims 2 to 7.
  • Another object of the invention is a method according to Claim 8 for the manufacture of a Virus-safe stable pharmaceutical preparation consisting of at least 70%, preferably 90% human, monomeric IgA.
  • an IgA that is essentially is to be obtained free of IgG which is present as a monomeric IgA and can be considered virus-safe, i.e. the infection with viruses after using this product can be excluded become.
  • an IgA preparation is used under monomeric IgA understood that at least 96 wt .-% monomeric IgA, based to the total amount of IgA.
  • the proportion of monomeric IgA in the stable pharmaceutical preparation is preferably at least 70%, most preferably 90%. Because of the high tendency of immunoglobulins to Treatment with chemical substances as used in processes used to inactivate viruses or at Heat treatment to form aggregates existed against one Treatment for inactivating viruses and in particular heat treatment has so far been rather a prejudice.
  • the IgA is not aggregated even if for example, heat treatment without the addition of more common ones Stabilizers, e.g. of carbohydrates or amino acids, is carried out.
  • Stabilizers e.g. of carbohydrates or amino acids
  • a preferred embodiment provides one Heat treatment before, and especially the heat treatment in Solution, where polyethylene glycol in a non-precipitating Amount to improve virus inactivating Effect is present.
  • PEG low molecular weight
  • the human IgA used in the method according to the invention containing starting material is preferably human Blood serum, plasma and / or plasma fractions.
  • the plasma and / or the Plasma fractions using the Cohn method with ethanol treated, and the Cohn II + III fraction is called Starting material used.
  • the IgA-containing starting material is purified by means of gel permeation chromatography and / or a thiophilic chromatography.
  • the IgA-containing starting material can also be prepurified, for example by precipitation with ethanol, polyethylene glycol and / or ammonium sulfate, and / or by another chromatographic method, for example using an ion exchanger, adsorption on hydroxylapatite, and / or dextran sulfate and / or a cleaning on Heparin-Sepharose®.
  • Other purification methods include precipitation of contaminating proteins with ZnSO 4 or Rivanol.
  • Pre-cleaning of this type means that the chromatography materials required for the further steps, for example the gel used in gel permeation chromatography, can be spared. As a result, the chromatography column can be used for a longer period of time, which is why the method according to the invention is also particularly suitable for use on an industrial scale.
  • IgG dimers For the separation of IgG dimers is preferably additionally affinity chromatography, e.g. on immobilized protein A or G, or on anti-IgG Antibodies coupled to a solid matrix.
  • This additional affinity chromatography can be done before Process stage (a), between process stage (a) and (b) and / or after process stage (b); .. expediently it is before or after chromatographic purification performed.
  • a process according to process stage (b) becomes the product obtained in the previous stages expediently used in dissolved or solid form.
  • the Product to be heat-treated preferably one Moisture content from 5 to 70% by weight.
  • a solid form Lyophilisate used.
  • a Heat treatment carried out this is preferably done at a temperature in the range between 40 ° C and 80 ° C and especially in the range between 50 ° C and 65 ° C.
  • the Heat treatment becomes at least one for the Deactivating viruses for a sufficiently long period of time carried out, and preferably for a period of 30 Minutes to 10 hours. This is preferably done Heat treatment as steam treatment, and especially after a method described in EP-A-0159311.
  • immunoglobulin-containing fractions Process for inactivating infectious agents subject are chemical or physical treatments expedient in the presence of a polyether, as described in DE-44 34 538 is described.
  • polyethers come for this purpose Polyhydroxy ethers such as polyalkylene glycol, and especially polyethylene or polypropylene glycol in question.
  • Dialysis against water can be performed, which results in any impurities still present, and in particular, if applicable, used or existing Stabilizing substances, largely removed.
  • hydrophilic / hydrophobic and / or electrostatic Gel permeation chromatography performed, i.e. a Gel permeation chromatography using a matrix that at the same time also a hydrophilic / hydrophobic or electrostatic interaction and affinity effects having.
  • This allows an excellent separation from Achieve IgG and IgA, which is surprisingly better than using a conventional one mentioned above Materials for gel permeation chromatography.
  • a gel of cross-linked agarose as it is for Fast Protein Liquid Gel Chromatography (FPLC®) from Biomolecules is used, e.g. Superdex® or Superose® (both from Pharmacia), or a gel from a synthetic Material used.
  • FPLC® Fast Protein Liquid Gel Chromatography
  • thiophile chromatography can also be carried out, and the combination of both purification methods is also possible.
  • Suitable adsorbents for thiophilic chromatography are preferably so-called T-gels based on carbohydrates or synthetic carrier materials, which contain structures such as R-SO 2 -CH 2 - or RS-CH 2 -CH 2 -SO 2 - and against sulfur-containing structures Proteins are targeted.
  • the adsorption of plasma or a plasma fraction on a thiophile matrix and the subsequent elution of a Fraction containing monomeric IgA also adjusts suitable method for producing a monomeric IgA containing preparation.
  • IgA1 and IgA2 are in the IgA produced and used according to the invention the subclasses IgA1 and IgA2 preferably in a ratio before that corresponds to the composition of native IgA.
  • the invention also relates to a pharmaceutical Preparation that is a human virus-safe monomeric IgA, optionally together with conventional ones contains pharmaceutical carriers and / or diluents.
  • the IgA that can be produced according to the invention it is possible to use a pharmaceutical composition to provide that is stable and virus-proof, and that too can be additionally heat treated.
  • the pharmaceutical composition according to the invention can besides the IgA also other active components (Active substances) included, provided they are compatible with IgA are and for the intended purpose of pharmaceutical Composition are suitable and appropriate.
  • active substances active substances
  • compositions according to the invention are especially for the prevention and treatment of Inflammation, infections and / or allergies are suitable.
  • IgA can be on local, mucosal, e.g. oral or systemic route.
  • the dosages depend on the route of administration and the Frequency of administration from, as well as the extent and the Severity of the disease, e.g. Inflammation. If high Total doses of IgA are administered, it is often preferred the IgA in several smaller doses during the To be distributed daily. These considerations in In terms of dosage and route of administration well known to a person skilled in the art.
  • IgA can e.g. oral (usually 1 to 10 g / day or, in severe cases, more) preferably in 3 or more doses respectively.
  • Immunoglobulin can also be administered mucosal, e.g. by inhalation (up to 10 ml / day, 10 to 100 mg IgA / ml), or nasally (15 to 200 mg / ml) using sprays or Drops, or locally by intra-articular injections (the if necessary 1 to 5 ml of a solution of 10 to 100 mg IgA / ml contain).
  • Other routes of administration include suppositories (100 to 1000 mg / IgA / dose) and transdermal patches. Transdermal patches can be used to Treat skin inflammation.
  • oral dosage forms such as e.g. Capsules, tablets, granules, pellets, mini pellets, Microcapsules used to treat viral bowel infections preferably with a gastric juice-resistant product, enteric coating are provided.
  • the daily dose of administration is pharmaceutical compositions according to the invention in the Rule 10 to 5000 mg, based on the inventive monomeric IgA. However, it is also based in particular the general condition and age of the patient, and according to the Disease severity.
  • the x-axis represents the elution volume in ml.
  • the suspension will 60 min with 18900 x g at 4 ° C to remove the insoluble Components centrifuged. The precipitation will discarded.
  • the supernatant is made with heparin-Sepharose CL-6B (Pharmacia-LKB, Uppsala, Sweden) transferred and overnight stirred at 4 ° C. Then the gel is passed through a nylon filter (85 mm mesh size) separated from the overhang. The gel is applied twice 0.9% NaCl solution washed (each with 1/4 of Sample volume). Supernatant and washing liquids will be united.
  • the unbound material is used for further IgA isolation used.
  • the plasminogen bound to the column can be another washing step with 100 ml of a buffer consisting of 50 mM sodium phosphate, 0.5 M NaCl, 0.2 M Epsilon aminocaproic acid, pH 7.5.)
  • the lysine-Sepharose-unbound material is replaced by a Precipitation with dextran sulfate (Sigma; sodium salt; MW: approx. 5000) Free of lipoproteins: 0.08 ml per ml of sample 10% dextran sulfate solution and 1 ml 1 M calcium chloride solution added. The mixture is stirred at 25-30 ° C. for 30 minutes and then centrifuged (18900 x g; 15 min; 4 ° C).
  • the dialyzed material is mixed with solid ammonium sulfate 4 ° C with stirring to a concentration of 2M. Then it is stirred for a further 30 min and then it becomes formed precipitate for 20 min at 1540 x g at 4 ° C centrifuged. (The supernatant is discarded.)
  • the precipitate is resuspended in phosphate-buffered isotonic saline solution pH 7.4 (hereinafter referred to as PBS) and dialyzed on an Amicon spiral module S1Y30 Cross Flow at room temperature against three times the sample volume of PBS.
  • IgA binds to the hydroxyapatite and can be eluted with 140 ml buffer B (15 mM NaHPO 4 / Na 2 HPO 4 in PBS with a pH of 6.8).
  • the material eluted from the hydroxyapatite with buffer B becomes an Amicon spiral module S1Y30 Cross Flow at room temperature against three times the sample volume 50 mM sodium acetate / acetic acid Buffer, pH 5.0, dialyzed.
  • the dialyzed material is treated with an anion exchanger in the Batch process offset.
  • This is the ion exchanger (Fractogel® EMD TMAE 650 (S); grain size 0.02-0.04 mm; Merck, Darmstadt, Germany; 1: 2 suspended in 50 mM Sodium acetate / acetic acid buffer, pH 5.0) added that per 10 mg protein 2 ml gel suspension available. The suspension is stirred at 4 ° C. overnight. Unbound material is separated using a suction filter and the gel twice with 50 mM sodium acetate / acetic acid buffer, pH 5.0 washed. The gel is then 2 hours at 4 ° C at 50 mM sodium acetate / acetic acid buffer + 80 mM NaCl, pH 6.0 touched. Then the gel is passed through a nutsche proteins eluted from this buffer.
  • the eluted material is transferred to an Amicon stirred cell a Diaflo ultrafiltration membrane YM30 to 10 mg protein / ml concentrated.
  • This material is passed through a Superdex® gel filtration column 200 Prep Grade HR 35/600 (Pharmacia-LKB) according to the invention separated: 10 ml of the sample are run on the in PBS, pH 7.4 equilibrated gel at a flow rate of 2.5 ml / min applied and eluted isocratically. With help Most of the IgG and other contaminants are separated from the IgA (Fig. 1 shows gel filtration on Superdex® 200 HR 35/600). The Fractions containing IgA are collected, pooled and continue with Protein G Sepharose 4 Fast Flow (Pharmacia-LKB; in PBS, pH 7.4, equilibrated) treated.
  • This Affinity chromatography is a batch process carried out, 1 ml of gel being used per 50 ml of sample. The suspension is stirred at 4 ° C. overnight. The gel will separated from the sample by centrifugation and 2x with PBS, pH 7.4 washed. Supernatant and washing solution are combined and in a dialysis tube (Spectrapor MWCO 12,000 - 14,000) dialyzed against distilled water.
  • the analysis of gel filtration is based on an analytical Superdex® 200 HR 10/30 FPLC column (Pharmacia-LKB) with PBS as Running buffer and a flow rate of 0.5 ml / min an FPLC system (Pharmacia-LKB).
  • the optical Density (OD) is measured at 280 nm in a flow cell measured and recorded against the elution volume (ml).
  • Fig. 2 shows that the end product consists largely of IgA monomers and a proportion of 5-10% IgA dimers, which form in solution from IgA monomers.
  • IgA aggregates are ⁇ 2%.
  • IgG cannot be detected by radial immunodiffusion, which means due to the sensitivity limit that less than 0.025 mg / ml IgG is available.
  • the end product produced in the manner according to the invention thus contains less than 1% IgG. Plasminogen and fibrinogen are also undetectable (Table 1).
  • the yield of IgA in relation to the starting material is 7 to 12%.
  • IgA, IgG and plasminogen are analyzed by radial immunodiffusion (Mancini G., Carbonara AO, Heremans JF, Immunochemistry 2 [1965] 235-254); Fibrinogen is detected by the method of Ouchterlony (Acta Path. Microbiol. Scand. 26 [1949] 507-515).
  • the still cloudy extract is precipitated with solid ammonium sulfate.
  • the final concentration of the solution is 2 M.
  • the precipitate is Centrifuged at 1540 x g at 4 ° C for 10 min. The supernatant is discarded. The precipitate is dissolved in PBS and opened replenished the initial volume.
  • dialysis dialysis tubing: Fa. Spectrapor, MWCO 12-14 kD
  • the dialyzed material is through Centrifugation and filtration through a 0.2 mm filter clarified.
  • the sample pretreated in this way (2 ml aliquot) is placed on a Superdex® 200 Prep Grade HR 16/60 column according to the invention separated and the fractions containing IgA isolated.
  • the sample isolated according to the invention is reduced Condition on SDS gel electrophoresis according to the system of Laemmli (Nature 227 [1970] 680-685) analyzed.
  • the gel will subjected to protein staining with Comassie Brilliant Blue and evaluated with a video densitometer (BIORAD).
  • the Intensity (OD) of the bands is compared to the migration distance in the Gel (mm) recorded.
  • Small amounts of IgG heavy chain ( ⁇ 10% of IgA) are observed. These residues of IgG can be caused by a subsequent Protein G Sepharose treatment removed become.
  • This method allows the isolation of IgA after clarification of the Starting material directly via the inventive Gel filtration method.
  • the yield of IgA in relation to the starting material is about 38%.
  • a pool is used as the starting material for the IgA isolation (at least 1000 donors) of human plasma.
  • the supernatant is 21% (w / v) PEG 6000 in 0.10M Tris-HCl, 0.150M NaCl buffer, pH 6.5) brought to a final concentration of 14% PEG and again 16 h at 4 ° C stirred. Then it is centrifuged again (6000 x g, 20 min, 4 ° C). The precipitation is with 300 - 350ml 0.1M Tris, 0.15M NaCl-HCl buffer (pH 8.0) dissolved and 4x against 5 l Double distilled water dialyzed (4 ° C, dialysis tube with 50 kilo dalton (kD) cut-off limit). The dialysate is through Centrifugation clarified. Dejected material will discarded.
  • Separation limit dialyzed against 5 l of isotonic saline The zinc sulfate concentration in this solution is brought to 0.1 M by slowly adding 2.5 M ZnSO 4 (dissolved in distilled water) to the dialysate. At the same time, the pH is kept at 6-8 (preferably 7) by adding 1 M Na 2 CO 3 in distilled water. The mixture is then stirred at 25 ° C. for 2 h and centrifuged off. The precipitate is discarded. The supernatant is dialyzed 3 times at 4 ° C. against double-distilled water.
  • This material (referred to as "zinc sulfate supernatant" in Table 2) contains approximately equal amounts of IgA and haptoglobin and small residues of IgG.
  • the dialyzed material after the zinc sulfate precipitation is with 1% rivanol (6,9-diamino-2-ethoxyacridine lactate in bidistilled water) to a final concentration of 0.1% (w / v) Rivanol brought.
  • rivanol (6,9-diamino-2-ethoxyacridine lactate in bidistilled water)
  • Rivanol brought.
  • the decreases pH due to lactic acid release
  • Holds with 0.01 M NaOH the pH of the mixture to 7.8-8.0.
  • 1 h stirred at room temperature and then centrifuged.
  • the Precipitation is discarded.
  • the supernatant becomes 3 to 6x 4 ° C dialyzed against double-distilled water.
  • the dialysate is via ultrafiltration (preferably in a Amicon stirred cell with Amicon YM10 membrane, Amicon, Beverly, MA, USA) concentrated.
  • the dialysed Rivanol supernatant undergoes a batch treatment with a cation exchanger (S-Sepharose® Fast Flow, Pharmacia-LKB):
  • Pretreatment of the S-Sepharose® Fast Flow 4 ml of the Gel suspension are removed with 6 ml of 0.2 M Tris / HCl buffer pH 8.0 added and centrifuged. The Gel cake is resuspended in 50 ml of 0.01 M Tris / HCl buffer pH 8.0 and centrifugation and washed as Suspension (1 part gel, 1 part buffer) in 0.01 M Tris / HCl buffer pH 8.0 removed. Before using centrifuged off part of the suspension, the supernatant discarded and the gel cake thus obtained for Adsorption tests used:
  • Rivanol supernatant 5 ml are adjusted to pH 8 with 2 M Tris base titrated.
  • This material is made up of 0.5 ml S-Sepharose® Fast Pipette flow gel. After 2 h incubation at 4 ° C (with shaking) is centrifuged off and the supernatant further purified by gel filtration: 2 ml aliquots of The supernatants are on a Superdex® 200 Prep Grade HR 16/60 FPLC column (Pharmacia-LKB) chromatographed. The IgA-containing fractions are collected and against water dialyzed. This material contains loudly Radial immunodiffusion analysis with at least 98% IgA. IgG and Haptoglobin could not be detected ( ⁇ 2%).
  • the anion exchange material with the attached ones Proteins are now further treated according to the invention: 100 g Paste are distilled in 1000 ml. Water suspended and through pulled a sintered nutsche.
  • the retained gel material is distilled with 2 l. water washed.
  • the washed gel material is washed with 300 ml of 0.5 M NaCl (in least Water dissolved), incubated at 4 ° C for 10 min and then centrifuged.
  • NaCl extract The supernatant (referred to as "NaCl extract” in Table 3) is lifted off and filtered sterile.
  • the extract becomes an equal volume Solution of 2 M ammonium sulfate, 0.1 M sodium acetate, pH 6.0, and this mixture, which is now 1 st Ammonium sulfate is on a thiophilic chromatography column applied.
  • the column (type XR-16/20 from Pharmacia-LKB) is 30 ml Affi-T Thiophilic Agarose (Kem-En-Tee, Copenhagen, Denmark) filled and with a solution of 1 M ammonium sulfate, 0.05 M Sodium acetate pH 6.0 equilibrated.
  • the fraction eluted with 0.6 M ammonium sulfate is countered 3 times least Water in a dialysis tube with a cut-off of 50 kD dialyzed.
  • the dialyzed material in Table 3 as "Ammonium sulfate eluate” is called) via ultrafiltration concentrated to about 3 mg / ml and then in 10 ml aliquots via a gel filtration column (Superdex® S200 Prep Grade HR 35/600, Pharmacia-LKB) chromatographed.
  • a gel filtration column Superdex® S200 Prep Grade HR 35/600, Pharmacia-LKB
  • the IgA-containing fractions are collected, pooled and dialyzed several times against PBS.
  • the yield of IgA, measured by the IgA content of the "NaCl extract” is about 22-30% (Table 3).
  • the material cleaned according to the invention consists of up to 95% from IgA as measured by radial immunodiffusion analysis was (Table 3).
  • Figure 5 shows the SDS polyacrylamide gel electrophoresis of the reduced sample according to the Laemmli system and subsequent densitometry (Description in Example 2) of the gel. Only that characteristic bands for the heavy (“IgA-HC”) and the light (“IGA-LC”) chains of the IgA are recognizable.
  • IgA with a purity of> 99% can be replaced by another Treatment with Protein G Sepharose Fast Flow (Pharmacia-LKB) be isolated in a batch process.
  • Pharmacia-LKB Protein G Sepharose Fast Flow
  • the amount of Protein G Sepharose should be measured so that 1 ml of gel material per 10 mg of IgG still contained in the batch is available. After incubation for 3 -6 hours with shaking the protein G Sepharose with the IgG bound to it separated by centrifugation. The supernatant is against distilled water dialyzed.
  • IgA preparations were made using IgA subclass-specific radial immunodiffusion plates (The Binding Site, Birmingham, England) on their IgA subclass composition tested (method according to Regulation from Binding Site) and with a plasma pool (from more than 1000 healthy, adult blood donors formed) compared: The composition of the IgA subclasses difference in the products produced according to the invention hardly differs from that of normal plasma (Table 4).
  • the light chain composition of the purified IgA was with Radial immunodiffusion plates from Behring (Marburg, Germany) examined (method according to the company Behring). There were no differences in the Kappa: Lambda ratio between purified IgA and one Standard plasma pool (in which the kappa: lambda ratio of all immunoglobulin classes was measured) (Table 5).
  • composition of the IgA produced according to the invention corresponds to the IgA contained in the serum.
  • the IgA subclass composition of the purified IgA preparations measured by radial immunodiffusion % IgA1 % IgA2 Plasma pool 79 21 IgA from Example 1 78 22 IgA from Example 3 76 24th IgA from Example 4 75 25th
  • the light chain composition of purified IgA measured by radial immunodiffusion (evaluation in units / dl) Kappa / Lambda Plasma pool 0.99 IgA from Example 3 0.95
  • Bacteria serve as the blank value fluorescence-labeled antibody, but not with IgA-containing Product (but instead with pure PBS) incubated were.
  • the analysis shows (Fig. 7, the x-axis defines the Intensity of fluorescence and the y-axis the number of detected bacteria) that the isolated according to the invention IgA binds to bacteria as well as the IgA from the Plasma pool. 74% of bacteria with plasma IgA and 77% the bacteria which are purified with IgA according to the invention incubated have bound IgA.
  • IgA isolated according to the invention is in distilled water dissolved in a concentration of 0.4 mg / ml and in one Water bath at different temperatures different incubated for a long time.
  • the material is then placed on a Superdex® 200 HR 10/30 gel filtration column as described in Example 1 analyzed.
  • a sample consisting essentially of IgA and IgG is obtained on different materials, but the same dimensioned gel filtration columns analyzed to the Influence of hydrophobic and / or electrostatic Test interactions with the column materials. To aliquots of the same size are applied to the columns and isocratic with identical elution conditions (0.5 ml / min) eluted.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP95110512A 1994-07-14 1995-07-05 Virussicheres stabiles pharmazeutisches Präparat bestehend aus wenigstens 70%, bevorzugt 90% humanem monomerem Immunglobulin A und Verfahren zu seiner Herstellung Expired - Lifetime EP0692491B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4424935A DE4424935C1 (de) 1994-07-14 1994-07-14 Humanes virussicheres monomeres Immunglobulin A und Verfahren zu seiner Herstellung
DE4424935 1994-07-14

Publications (2)

Publication Number Publication Date
EP0692491A1 EP0692491A1 (de) 1996-01-17
EP0692491B1 true EP0692491B1 (de) 2001-10-10

Family

ID=6523192

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95110512A Expired - Lifetime EP0692491B1 (de) 1994-07-14 1995-07-05 Virussicheres stabiles pharmazeutisches Präparat bestehend aus wenigstens 70%, bevorzugt 90% humanem monomerem Immunglobulin A und Verfahren zu seiner Herstellung

Country Status (8)

Country Link
US (1) US5808000A (ja)
EP (1) EP0692491B1 (ja)
JP (1) JP2955211B2 (ja)
AT (2) ATE206718T1 (ja)
CA (1) CA2153858A1 (ja)
DE (2) DE4424935C1 (ja)
DK (1) DK0692491T3 (ja)
ES (1) ES2165884T3 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541399B2 (en) 2002-02-19 2013-09-24 Resolution Chemicals Limited Solvent-based sterilisation of pharmaceuticals

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19600939C1 (de) 1996-01-12 1997-08-28 Immuno Ag Verfahren zur Trennung von IgG und IgA
BE1012448A3 (fr) * 1998-12-07 2000-11-07 S C R L Dept Central De Fracti Standard utilise dans des tests de diagnostic et/ou de quantification.
AU2001247827B2 (en) * 2000-03-27 2005-09-01 Medarex, Inc. Methods for immunostimulation using binding agents for the FC receptor of immunoglobulin A
US20010051147A1 (en) * 2000-03-27 2001-12-13 Van De Winkel Jan G.J. Methods for immunostimulation using binding agents for the Fc receptor of immunoglobulin A
US20020098182A1 (en) * 2000-09-28 2002-07-25 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
CA2423805A1 (en) * 2000-09-28 2002-04-04 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin g
US6932967B2 (en) * 2001-03-22 2005-08-23 Michael R. Simon Human medical treatment by aerosol inhalation of immunoglobulin A
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US20040180045A1 (en) * 2001-09-28 2004-09-16 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
WO2007035870A2 (en) 2005-09-20 2007-03-29 Prolacta Bioscience, Inc. A method for testing milk
WO2007074350A1 (en) * 2005-12-28 2007-07-05 Andrea Marinello Device for the treatment of carotid artery diseases
EP2069387A4 (en) * 2006-06-14 2011-02-02 Glaxosmithkline Llc METHODS OF PURIFYING ANTIBODIES USING HYDROXYAPATITE CERAMIC
ES2634613T3 (es) * 2006-08-30 2017-09-28 Prolacta Bioscience, Inc. Métodos de obtención de leche estéril y composiciones de la misma

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT359641B (de) * 1978-09-19 1980-11-25 Immuno Ag Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates
US4186192A (en) * 1978-12-18 1980-01-29 Cutter Laboratories, Inc. Stabilized immune serum globulin
JPS5759815A (en) * 1980-09-30 1982-04-10 Mochida Pharmaceut Co Ltd Drug composition having preventing and remedying action on rotavirus infectious disease
EP0050061B2 (en) * 1980-10-06 1990-06-20 New York Blood Center, Inc. Method of reducing undesirable activities of biological and pharmaceutical products
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
ATE59144T1 (de) * 1984-07-07 1991-01-15 Armour Pharma Gmbh Verfahren zur herstellung von gamma-globulin zur intravenoesen anwendung.
JPH0669961B2 (ja) 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
JP3145696B2 (ja) * 1990-10-05 2001-03-12 日本ケミカルリサーチ株式会社 分泌型免疫グロブリンａ製剤の製造法
AT402789B (de) * 1991-03-25 1997-08-25 Immuno Ag Pharmazeutische präparation auf basis von plasmaproteinen
DE4125625C2 (de) * 1991-08-02 1999-12-02 Octapharma Ag Glarus Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen
US5258177A (en) * 1991-12-10 1993-11-02 Alpha Therapeutic Corporation IgA preparation and process of making the same
CH684164A5 (de) * 1992-01-10 1994-07-29 Rotkreuzstiftung Zentrallab Intravenös anwendbare Immunglobulinlösung.
DE4434538C2 (de) * 1993-10-06 2000-08-10 Immuno Ag Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541399B2 (en) 2002-02-19 2013-09-24 Resolution Chemicals Limited Solvent-based sterilisation of pharmaceuticals

Also Published As

Publication number Publication date
JPH0859699A (ja) 1996-03-05
ATA118995A (de) 1999-08-15
DE59509679D1 (de) 2001-11-15
CA2153858A1 (en) 1996-01-15
EP0692491A1 (de) 1996-01-17
ES2165884T3 (es) 2002-04-01
DE4424935C1 (de) 1996-03-21
ATE206718T1 (de) 2001-10-15
AT406265B (de) 2000-03-27
DK0692491T3 (da) 2001-12-03
US5808000A (en) 1998-09-15
JP2955211B2 (ja) 1999-10-04

Similar Documents

Publication Publication Date Title
DE69920693T2 (de) Verfahren zur herstellung von immunoglobulinen zur intravenösen verabreichung und anderen immunoglobulin-produkten
DE2751717C2 (ja)
EP0692491B1 (de) Virussicheres stabiles pharmazeutisches Präparat bestehend aus wenigstens 70%, bevorzugt 90% humanem monomerem Immunglobulin A und Verfahren zu seiner Herstellung
DE69027187T2 (de) Verfahren zur inaktivierung von viren in mit viren verunreinigten pharmazeutischen zusammensetzungen
EP0784632B1 (de) Verfahren zur gewinnung von hochreinem von willebrand-faktor
DE3825429C2 (de) Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
DE3734923C1 (de) Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt
DE69017050T2 (de) Verfahren zur isolierung von faktor viii.
DE69821741T2 (de) Immunoglobulin enthaltende zusammensetzung
EP0447585B1 (de) Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates
DE3686470T2 (de) Verfahren zur herstellung des alpha-1-proteinase-inhibitors.
EP0413188B1 (de) Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oder IgA-haltige Immunglobulinpräparate
EP0268973A2 (de) Verfahren zur Herstellung eines virussicheren, lagerstabilen und intravenös verträglichen Immunglobulin-G-Präparates
DE3889938T2 (de) Injizierbare Lösungen von Gamma-Globulin.
EP0085747B2 (de) Intravenös verabreichbares humanes Immunglobulin und Verfahren zu dessen Herstellung
AT390560B (de) Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
DE69733548T2 (de) Reinigungsverfahren
EP0252064B1 (de) Gegen Pseudomonas aeruginosa Infektionen wirksame Präparationen und Verfahren zu ihrer Herstellung
DE68918761T2 (de) Therapeutische IgM-Konzentrate.
EP0873362B1 (de) VERFAHREN ZUR TRENNUNG VON IgG und IgA
EP0234405B1 (de) Verwendung eines immunglobulinhaltigen Präparates zur Prophylaxe und Therapie von AIDS beim Menschen
DE3688713T2 (de) Verfahren zur Stabilisierung eines Urokinasevorläufers und diesen Vorläufer enthaltendes trockenes Präparat.
AT367297B (de) Verfahren zur herstellung eines serumeiweiss-pr[parates
EP0812858A1 (de) Verfahren zur Herstellung einer Faktor VIII-enthaltenden Zusammensetzung
CH646609A5 (en) Gamma-globulin for intravenous injection

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IE IT LI NL SE

17P Request for examination filed

Effective date: 19960201

17Q First examination report despatched

Effective date: 19981014

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAXTER AKTIENGESELLSCHAFT

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RTI1 Title (correction)

Free format text: STABLE PHARMACEUTICAL PREPARATION CONSISTING OF AT LEAST 70%, PREFERABLY 90% HUMAN VIRUS-FREE MONOMERIC IMMUNOGLOBULIN A AND METHOD FOR ITS PRODUCTION

RTI1 Title (correction)

Free format text: VIRUS SAFE STABLE PHARMACEUTICAL PREPARATION CONSISTING OF AT LEAST 70%, PREFERABLY 90% HUMAN MONOMERIC IMMUNOGLOBULIN A AND METHOD FOR ITS PRODUCTION

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB IE IT LI NL SE

REF Corresponds to:

Ref document number: 206718

Country of ref document: AT

Date of ref document: 20011015

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20011011

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: GERMAN

REF Corresponds to:

Ref document number: 59509679

Country of ref document: DE

Date of ref document: 20011115

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BUECHEL, KAMINSKI & PARTNER PATENTANWAELTE ESTABLI

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2165884

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20030702

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20030718

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20030721

Year of fee payment: 9

Ref country code: IE

Payment date: 20030721

Year of fee payment: 9

Ref country code: CH

Payment date: 20030721

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20030722

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20030731

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20030807

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20030911

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20040616

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20040621

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040705

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040705

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040706

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040706

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040731

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040802

BERE Be: lapsed

Owner name: *BAXTER A.G.

Effective date: 20040731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050201

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20040705

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050331

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050705

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050705

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20040706

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060201

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20060201

BERE Be: lapsed

Owner name: *BAXTER A.G.

Effective date: 20040731